GlassScriptPhysician profile
Rushir J Choksi
NPI 1851553663
$38,155.79
in general payments reported to CMS, 2019-2025
35 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $4,134 · 2021: $409 · 2022: $1,195 · 2023: $884 · 2024: $1,674 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,678.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $10,281.01 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $10,112.23 | 2019-2024 | Onivyde, Somatuline Depot |
| Verastem, INC. | $6,061.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $2,380.79 | 2019-2025 | Calquence, Lynparza |
| Exelixis INC. | $2,026.57 | 2019 | |
| Dendreon Pharmaceuticals LLC | $1,635.22 | 2019 | |
| Secura Bio, INC. | $1,598.46 | 2020 | |
| Genzyme Corporation | $524.84 | 2019-2025 | |
| Beigene USA, INC. | $441.34 | 2022 | |
| Heron Therapeutics, INC. | $332.12 | 2022-2025 | |
| Celgene Corporation | $303.53 | 2019-2025 | Reblozyl, Opdivo |
| Abbvie INC. | $299.09 | 2023-2025 | Venclexta |
| Novartis Pharmaceuticals Corporation | $280.63 | 2023-2025 | |
| Janssen Biotech, INC. | $227.00 | 2019-2025 | Carvykti, Tecvayli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.21 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $196.41 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $189.02 | 2024-2025 | Keytruda, Welireg |
| Genmab U.S., INC. | $142.66 | 2024 | Epkinly |
| Gilead Sciences, INC. | $128.91 | 2022-2025 | Trodelvy |
| Array Biopharma INC | $116.98 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Glaxosmithkline, LLC. | $101.34 | 2024 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $90.78 | 2021-2025 | Opdivo, Augtyro |
| Stemline Therapeutics INC. | $84.60 | 2024-2025 | Orserdu |
| Lilly USA, LLC | $71.63 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Mylan Institutional INC. | $52.94 | 2019 | |
| Acrotech Biopharma INC. | $51.10 | 2021-2025 | Beleodaq |
| Daiichi Sankyo INC. | $42.38 | 2024-2025 | Enhertu, Vanflyta |
| Regeneron Healthcare Solutions, INC. | $41.26 | 2023 | Libtayo |
| Puma Biotechnology, INC. | $25.18 | 2020 | |
| Beone Medicines USA, INC. | $24.56 | 2025 | Brukinsa |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Rigel Pharmaceuticals, INC. | $18.69 | 2024 | Rezlidhia, Tavalisse |
| Blueprint Medicines Corporation | $18.09 | 2025 | Ayvakit |
| Taiho Oncology, INC. | $17.05 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.80 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rushir Choksi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.